Lunacalcipol (vitamin D hormone analog) / OPKO Health - LARVOL DELTA

Focusing on non-responders to infliximab with ulcerative colitis, what can we do first and next? (PubMed, Int Immunopharmacol) - "This study developed a novel prediction model for pre-assessing the efficacy of IFX in patients with UC, as the first step towards personalized therapy. Meanwhile, drugs and non-coding RNAs were provided as potential candidates to develop the next-step precise treatment for the predicted non-responders. In particular, Defeasirox appears to hold promise as an adjuvant or alternative to IFX for the optimization of UC therapy."

Journal • Colorectal Cancer • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CYP24A1